Bal Pharma Share Price

NSE
BALPHARMA •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Bal Pharma Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
35.75% Fall from 52W High
-15.3
TTM PE Ratio
Below industry Median
22.3
Price to Book Ratio
2.3
Dividend yield 1yr %
Below industry Median
1.2
TTM PEG Ratio
PEG TTM is less than 1
0.2

Bal Pharma Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Bal Pharma Ltd Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
73.15 Cr
73.69 Cr
74.36 Cr
94.63 Cr
81.66 Cr

Bal Pharma Ltd Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
342.07 Cr
305.16 Cr
286.37 Cr
251.67 Cr
172.93 Cr

Bal Pharma Ltd Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
0.52 Cr
1.04 Cr
0.26 Cr
5.53 Cr
0.85 Cr

Bal Pharma Ltd Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
7.45 Cr
2.62 Cr
5.7 Cr
4.71 Cr
-12.89 Cr

Bal Pharma Ltd shareholding Pattern

Promoter
50.9%
Foreign Institutions
0.1%
Public
49%
Promoter
50.9%
Foreign Institutions
0.1%
Public
49%
Promoter
51.2%
Foreign Institutions
0.1%
Public
48.6%
Promoter
51.2%
Foreign Institutions
0.1%
Public
48.6%
Promoter
51.2%
Foreign Institutions
0.1%
Public
48.6%
Promoter
51.6%
Foreign Institutions
0.1%
Public
48.2%

Bal Pharma Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
5Day EMA
103.00
10Day EMA
105.70
12Day EMA
106.50
20Day EMA
109.10
26Day EMA
110.60
50Day EMA
114.80
100Day EMA
118.50
200Day EMA
117.90
5Day SMA
103.40
10Day SMA
107.50
20Day SMA
109.30
30Day SMA
112.40
50Day SMA
116.60
100Day SMA
121.80
150Day SMA
123.50
200Day SMA
120.50
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
19946 Rs
33810 Rs
Week Rs
11877 Rs
20202 Rs
Month Rs
10176 Rs
18776 Rs
Resistance & Support
100.53
Pivot
Resistance
First Resistance
104.66
Second Resistance
107.81
Third Resistance
111.94
Support
First Support
97.38
Second support
93.25
Third Support
90.10
Relative Strength Index
37.14
Money Flow Index
36.57
MACD
-4.05
MACD Signal
-3.22
Average True Range
6.20
Average Directional Index
20.77
Rate of Change (21)
-12.91
Rate of Change (125)
-11.59

Bal Pharma Ltd Company background

Founded in: 1987
Managing director: Shailesh Siroya
Bal Pharma Ltd (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May 87. In Mar.90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations.BPL manufactures and markets pharmaceutical formulations paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.95 for manufacture of bulk drugs and expansion of pharmaceutical formulations.During 199798, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited. The companys product range has been expanded with the introduction of AZIWIN, CAFIMOL CORTIDERM.The company has added further product range Zanovid, Aziwin, Dry Syrup, Meloxi, Ocium M, Progit MPS in its ethical division during 19992000. As part of the expansion of the product range, the company has introduced Cardiac Specialities Products. To market these products, a new division named SERVETUS has started functioning during 2001. New products like Amiloride,Benzydamine and Ebastine were rolled into the market during 2002. The commercial production of Formulation Plant in Uttarakhand started from 1st January, 2009. The Company floated Lifezen Healthcare Pvt Ltd during the year 201415 as its subsidiary. It ventured into heath care sector through its subsidiary i.e. Balance Clinics LLP. In 201617, it commenced its project on construction of an fully integrated API unit with an annual production capacity of 270 metric tonnes of assorted API products including Gliclazide, Ebastine, Amiloride HCL, Benzydamine HCL, Pregablin etc, located at Gauribidanur near Bangalore with an estimated investment of Rs 45 Crores. In 201718, the Company acquired 100% stake and management control of Golden Drugs Private Ltd, an Udaipur, Rajasthan involved in the manufacture of bulk drugs and intermediates costing Rs 14 Crores. It earmarked Rs. 36 Cr. for setting up of an bulk drugsmanufacturing unit at Yadgir District , Karnataka in year 202223. It launched Sitagliptin (a DPP4 Inhibitor) in the plain form, and as a combination with Metformin under the brand names SITABEND SITABENDM, respectively in 2023.
Read More

Bal Pharma Ltd FAQs

Bal Pharma Ltd share price is ₹101.5 in NSE and ₹100.6 in BSE as on 12/2/2025 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

Bal Pharma Ltd share price in the past 1-year return was -9.57. The Bal Pharma Ltd share hit a 1-year low of Rs. 88.95 and a 1-year high of Rs. 157.98.

The market cap of Bal Pharma Ltd is Rs. 161.6 Cr. as of 12/2/2025 12:00:00 AM.

The PE ratios of Bal Pharma Ltd is 14.79 as of 12/2/2025 12:00:00 AM.

The PB ratios of Bal Pharma Ltd is 1.51 as of 12/2/2025 12:00:00 AM

You can easily buy Bal Pharma Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -